tirzepatide to semaglutide Outperforms in Blood Sugar Control Switching Semaglutide to Tirzepatide: A
Description
Tirzepatide is administered subcutaneously once weekly at doses ranging from 2.5 mg to 15 mg, with gradual dose escalation recommended to minimize gastrointestinal adverse effects
It works by increasing insulin release, reducing glucose production, and slowing digestion
The Beyond Use Date assumes proper storage throughout
Poor sleep can disrupt the gut microbiome and exacerbate digestive issues
a gritty, burning, or something-in-my-eye sensation
Tesamorelin (growth hormone releasing hormone) pairs well for muscle preservation
